Small Pharma listed on the TSX-V under ticker symbol DMT on 6th May 2021.

The company describes themselves on their website as ‘a neuropharmaceutical company specialised in IP led development of novel treatments for mental health conditions, with a focus on depression. Small pharma initiated a clinical program into DMT assisted therapy in February 2021. This program includes a Phase I/IIa on their lead candidate alongside development of a robust pipeline of proprietary preclinical assets’.